[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Heba Ahmed Mohamed\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100621101","prognostic-value-of-dhodh-expression-in-hgsoc-a-comparative-study-between-neoadjuvant-and-adjuvant-chemotherapy-settings-100621101",false,"NCT07366242","Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings","Prognostic Value of Dihydroorotate Dehydrogenase (DHODH) Expression in High-Grade Serous Ovarian Carcinoma: A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings","HGSOC","Inclusion Criteria:\n\n* Histologically confirmed high-grade serous ovarian carcinoma\n* Availability of adequate FFPE tumor tissue\n* Known treatment modality (PDS or IDS)\n* Available clinical follow-up including platinum-free interval and survival data\n\nExclusion Criteria:\n\n* Non-serous histological subtypes\n* Low-grade serous carcinoma\n* Inadequate tissue for immunohistochemistry\n* Missing clinical or follow-up data","FEMALE",{"count":19,"type":20},72,"ESTIMATED","OBSERVATIONAL","* To compare DHODH protein expression in HGSC tissues from patients undergoing Primary Debulking Surgery (PDS - Chemo-naive) versus Interval Debulking Surgery (IDS - Post-NACT).\n* To evaluate the association between DHODH expression and the degree of chemotherapy response (using the Chemotherapy Response Score - CRS for NACT cases).\n* To determine the prognostic value of DHODH expression in predicting Platinum-Free Interval (PFI) ,Progression -Free Survival (PFS) and Overall Survival (OS) across both groups.",[15],"NOT_YET_RECRUITING","2026-01-16",{"date":27,"type":28},"2026-01-26","ACTUAL",{"date":30,"type":20},"2026-06-01",{"date":32,"type":20},"2027-07-01",{"name":34,"class":35},"Heba Ahmed Mohamed","OTHER",""]